Tamtam Try Tamtam free
Abbott logo

Abbott account plan

Healthcare and life technologies

At a glance

Abbott is a diversified healthcare group in medical devices, diagnostics, nutrition and branded generics: $44,328 million FY2025 net sales, 122,000 staff.

Abbott Laboratories develops, manufactures and sells medical devices, diagnostic systems and tests, pediatric and adult nutrition, and branded generic medicines to hospitals, laboratories, pharmacies, retailers, governments and consumers in more than 160 countries. FY2025 net sales were $44,328 million (+5.7%), with operating earnings of $8,053 million and net earnings of $6,524 million; international markets were 61% of sales and emerging markets 37%. It had about 115,000 employees at December 31, 2025 (69% outside the U.S.) and cited 122,000 colleagues in its Q2 2026 release. Abbott is incorporated in Illinois and led by Chairman and CEO Robert B. Ford; it closed the acquisition of Exact Sciences on March 23, 2026, entering cancer diagnostics.

Business units

Strategic priorities

Sustained 7% top-line growth
Robert Ford said "7% is still the right target" for sales growth on the Q2 2026 call: Nutrition 2%-4%, Diagnostics 7%-8%, EPD 7%-9% and MedTech 8%-10%, aiming for high single-digit sales and double-digit EPS growth.
Expand continuous glucose monitoring
Abbott sees 75 to 80 million people who could realistically use a CGM versus 15 million today; U.S. type 2 non-insulin coverage would open about 10 million Medicare beneficiaries. Libre Duo, a dual glucose-ketone sensor, got its CE Mark in May 2026.
Build cancer diagnostics
After closing Exact Sciences, Abbott aims to cover screening, therapy selection and MRD testing; Cancer Diagnostics grew 13% in Q2 2026 with mid-teens Cologuard growth, and care gap programs with health systems ramp in the second half.
Win in electrophysiology
Volt PFA moves to full U.S. release in Q3 2026, with Abbott "selling the entire procedure" (PFA catheters, mapping, ICE, introducers) and PFA iterations planned through 2029; Amulet 360 may be approved by year-end.
Restore Nutrition and Structural Heart growth
Q4 2025 price cuts and launches (high-protein low-sugar Ensure, a collagen protein shake, a whole-milk infant formula) target Nutrition volumes; in U.S. mitral, Abbott made personnel changes to fix commercial execution.
R&D pipeline
R&D is targeted at about 7% of sales in 2026. Trials starting include balloon-expandable TAVR, leadless conduction system pacing, a Cephea mitral replacement valve, peripheral IVL and a wearable lactate sensor, targeting contributions in 2029-2030.

Latest results

In Q2 2026 (quarter to June 30) net sales were $12,593 million, +13.0% reported and +4.8% on a comparable basis that includes Exact Sciences in both years. Medical Devices grew 8.4% and Established Pharmaceuticals 8.7% comparable, Diagnostics 2.9% (Cancer Diagnostics +13.3%, Rapid/Molecular -8.0%) and Nutrition fell 3.6%. GAAP net earnings fell to $928 million ($0.53 diluted EPS) from $1,779 million on higher amortization, integration costs, legal reserves and interest; adjusted diluted EPS was $1.31 vs $1.26. Full-year 2026 guidance: comparable sales growth of 6.5% to 7.5% reaffirmed and adjusted diluted EPS raised to $5.45-$5.60, with Q3 adjusted EPS of $1.38-$1.46.

Investments and deals

Exact Sciences acquisition
Completed March 23, 2026 for about $20.6 billion ($105 per share in cash), funded mainly by $20.0 billion of long-term debt; Abbott also repaid nearly all of about $2.8 billion of assumed debt. Exact Sciences had $3.247 billion of 2025 sales and is expected to add about $3 billion in 2026.
Fifth CGM sensor plant
Abbott is in the final stages of planning a fifth sensor plant, which Ford said would "probably be a billion dollar investment", as its fourth plant nears capacity.
Capex and R&D
FY2025 capex was $2.2 billion and R&D $2.9 billion; Q2 2026 R&D rose 22.9% to $892 million.
Shareholder returns
Abbott returned $2.1 billion to shareholders in Q2 2026; the quarterly dividend is $0.63 per share, raised for 54 consecutive years, and $5.6 billion of buyback authorisation remained at June 30, 2026.

Challenges and risks

Higher debt after Exact Sciences
Net interest expense rose $249 million to $299 million in Q2 2026 and cash fell from $8.5 billion to $5.1 billion in the first half; the 10-K flagged the extra borrowing as a risk to flexibility and credit ratings.
China and COVID-19 testing in Diagnostics
Volume-based procurement drove China Core Lab declines of 15% to 30% a quarter in 2025, and COVID-19 testing sales fell from $1.6 billion in 2023 to $297 million in 2025; Diagnostics operating margin dropped from 24.4% in 2023 to 19.5% in 2025.
Infant formula litigation
1,760 preterm infant formula (NEC) lawsuits were pending at January 31, 2026; the Missouri Court of Appeals affirmed a $495 million verdict in May 2026, and a DOJ criminal investigation into powdered infant formula manufacturing is ongoing.
Nutrition volumes
Nutrition sales fell 5.6% in the first half of 2026 on lower adult and U.S. pediatric volumes, with U.S. Pediatric down 11.9%.
Tariffs, regulation and supply chain
The 10-K lists supply chain disruption, cybersecurity, FDA and EU MDR/IVDR regulation, cost containment, tariffs, geopolitics and FX among its main risks.

What leadership says

“We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”

Robert B. Ford, Chairman and Chief Executive Officer · Abbott Reports Second-Quarter 2026 Results, July 16, 2026

“7% is still the right target”

Robert B. Ford, Chairman and Chief Executive Officer · Q2 2026 earnings call, July 16, 2026, on long-term top-line growth

“I am never going to make a long-term strategic decision based on near-term challenges.”

Robert B. Ford, Chairman and Chief Executive Officer · Q1 2026 earnings call, April 16, 2026, on the Nutrition portfolio

Where a supplier can help

Manufacturing capacity for CGM
The planned fifth sensor plant, a roughly billion-dollar investment, opens needs for equipment, automation, construction and supply chain partners.
Integrating Exact Sciences
Integration of a $20.6 billion acquisition, with integration expenses already weighing on SG&A, creates work in systems, finance, data and commercial operations alignment.
Commercial execution in cancer screening
Care gap programs tied to health systems' HEDIS and star ratings and the Cologuard rescreen funnel are growth levers where patient engagement, analytics and outreach tools can help.
Cost and margin programmes
With higher interest costs and margin initiatives behind the gross margin gains, suppliers offering procurement, logistics or operating-cost savings align with management's focus.
Regulatory and quality compliance
EU MDR/IVDR transitions and the infant formula manufacturing scrutiny point to demand for quality, compliance and manufacturing-traceability solutions.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Abbott?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Abbott

What does Abbott do?

Abbott makes and sells medical devices (including FreeStyle Libre CGM), diagnostic systems and tests, pediatric and adult nutrition, and branded generic medicines in more than 160 countries.

What is Abbott's revenue?

FY2025 net sales were $44,328 million, up 5.7%, with net earnings of $6,524 million. Q2 2026 sales were $12,593 million, and 2026 guidance is 6.5% to 7.5% comparable sales growth.

How many employees does Abbott have?

About 115,000 at December 31, 2025, 69% outside the U.S.; the Q2 2026 release cited 122,000 colleagues after the Exact Sciences acquisition.

Who leads Abbott?

Robert B. Ford is Chairman and Chief Executive Officer; Philip P. Boudreau is EVP Finance and CFO.

What is Abbott's strategy?

Abbott targets about 7% top-line growth, led by CGM expansion, electrophysiology, cancer diagnostics from Exact Sciences and a recovery in Nutrition, with R&D at about 7% of sales.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)